Twenty per cent rule-out
| Pathway | Proportion of non-cancers ruled-out (specificity) (95% CI) | Negative predictive value (95% CI) | Sensitivity (95% CI) |
| Breast | 0.2036 (0.1926 to 0.2143) | 0.9936 (0.9883 to 0.9981) | 0.9776 (0.9596 to 0.9933) |
| Lower Gastrointestinal | 0.2002 (0.1921 to 0.2081) | 0.9823 (0.9762 to 0.9877) | 0.9348 (0.9135 to 0.9543) |
| Upper Gastrointestinal | 0.2017 (0.1901 to 0.2137) | 0.9880 (0.9806 to 0.9946) | 0.9580 (0.9323 to 0.9804) |
| Gynaecological | 0.2040 (0.1871 to 0.2209) | 0.9895 (0.9799 to 0.9979) | 0.9718 (0.9462 to 0.9942) |
| Urological | 0.2002 (0.1864 to 0.2141) | 0.9525 (0.9358 to 0.9680) | 0.9681 (0.9568 to 0.9785) |
| Lung | 0.2031 (0.1704 to 0.2331) | 0.9630 (0.9281 to 0.9924) | 0.9673 (0.9364 to 0.9933) |
| Haematological | 0.2095 (0.1694 to 0.2542) | 0.9375 (0.8795 to 0.9868) | 0.9697 (0.9408 to 0.9938) |
| Head and neck | 0.2001 (0.1862 to 0.2139) | 0.9748 (0.9623 to 0.9858) | 0.9267 (0.8917 to 0.9580) |
| Skin | 0.2002 (0.1868 to 0.2130) | 0.9406 (0.9232 to 0.9570) | 0.9609 (0.9493 to 0.9717) |